

Special Issue

Advances in COVID-19 Vaccines and Neutralizing Antibody

Message from the Guest Editors

Antibody immune response is important for the clearance of the virus and critical for the generation of memory response to prevent reinfection. SARS-CoV-2 generates a virus-specific IgM, and IgG and neutralizing IgG response in the days following infection. However, the IgG response wanes over time and in some cases leads to only partial protection. There is a need for further research in this field to understand the measure/degree of long-term protection conferred by the vaccine, vaccine-driven pathology, and immune differences among patients. In this Special Issue, we invite articles investigating antibody response to coronavirus, including but not limited to the role of neutralizing antibodies in SARS-CoV-2 infection, mechanisms that lead to viral escape, immune parameters correlated with cytokine release syndrome, and T cell and B cell dynamics in coronavirus infection. Research in this field will aid in further understanding the pathogenesis of the disease and in the development of improved vaccine strategies.

Guest Editors

Dr. Rishi Jaiswal

Dr. Srijani Basu

Dr. Suman Gupta

Dr. Sneha Lata Gupta

Deadline for manuscript submissions

closed (10 February 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/127918

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).